Patient Selection for Treatment

Fig. 13.1
Peritoneal carcinomatosis from ovarian cancer: involvement of lesser omentum and hepatoduodenal ligament


Fig. 13.2
Lesser omentectomy and stripping of the omental bursa floor

Another challenging problem, especially in patients with CRC, concerns coexisting PC with liver metastases. A meta-analysis conducted by Dutch investigators showed a trend toward lower OS after curative resection plus HIPEC in patients with CRC metastases in the liver, as well as in the peritoneum, than in patients with peritoneal metastases alone after the same treatment [48]. Although this approach can be used to treat PC and liver metastases during the same procedure in selected patients, only patients who have limited peritoneal spread (PCI < 12) and a limited extent of liver disease (liver metastases < 3) really benefit from this approach, with a median survival of 40 months [49].

13.5 Decision Making

In his “Presidential Address to the Society of Surgical Oncology,” Blake Cady stated that tumor biology is the king, patient selection is the queen, and technical procedure the prince, of the kingdom. Only rarely does the prince usurp the kingdom [50]. These considerations perfectly illustrate the problem being addressing. Patient selection criteria must maintain the balance between opposing forces. On the one side is a frequently unfavorable and undoubtedly aggressive tumor biology; on the other side is a surgeon convinced that technical efforts will snatch the patient away from an ineluctable destiny. Ideal selection criteria should indicate patients for whom surgery is most likely to have a successful outcome and therefore in whom technical, organizational, and economic efforts, necessitated by these procedures, should be invested.

Research over the past few years, limited to PC from CRC, has developed a staging classification intended chiefly for preoperative use [Peritoneal Surface Disease Severity Score (PSDSS)], which analyzes separately the entity of patient symptoms, the extent of peritoneal disease (PCI), and the histopathologic tumor features (including lymphatic spread), yielding a specific score and then subdivided into four stages (Fig. 13.3) [32]. The American Society of Peritoneal Surface Malignancies conducted a retrospective review of 609 patients who underwent CRS plus HIPEC after PSDSS staging. Their findings show that the PSDSS, assessed before surgery, can define a population with a statistically high or notably low likelihood of long-term survival (Fig. 13.4) [51].


Fig. 13.3
Peritoneal Surface Disease Severity Score (PSDSS). (Reproduced from [52], with permission)


Fig. 13.4
Long-term survival according to the Peritoneal Surface Disease Severity Score (PSDSS). (Reproduced from [52], with permission)

Regardless, whatever the pros and cons of one scoring system or another, the intellectual rationale for selecting patients as candidates for CRS plus HIPEC procedures never concerns the surgeon alone. The decision inevitably requires a multidisciplinary contribution involving many specialists and includes the patients themselves so as to offer an individualized treatment option. Especially important is the need to alert the medical community (medical oncologists, the message is for you) that PSM is not by definition incurable. Quite the contrary: CRS plus HIPEC offers many of these patients a real chance of cure. Only keeping these management options firmly in mind will increase the number of patients referred to expert centers for treatment, help identify patients with PSM at earlier stages and thus simplify patient selection.



Mohamed F, Moran BJ (2009) Morbidity and mortality with cytoreductive surgery and intraperitoneal chemotherapy: the importance of a learning curve. Cancer J 15:196–199CrossRefPubMed


Herzog TJ (2012) The role of heated intraperitoneal chemotherapy (HIPEC) in ovarian cancer: hope or hoax? Ann Surg Oncol 19:3998–4000CrossRefPubMed


Reuter NP, Macgregor JM, Woodall CE et al (2008) Preoperative performance status predicts outcome following heated intraperitoneal chemotherapy. Am J Surg 196:909–913CrossRefPubMed


Shen P, Hawksworth J, Lovato J et al (2004) Cytoreductive surgery and intraperitoneal hyperthermic chemotherapy with mitomycin C for peritoneal carcinomatosis from nonappendiceal colorectal carcinoma. Ann Surg Oncol 11:178–186CrossRefPubMed


Levine EA, Stewart JH, Shen P et al (2014) Intraperitoneal chemotherapy for peritoneal surface malignancy: experience with 1,000 patients. J Am Coll Surg 218:573–585CrossRefPubMed


Baratti D, Kusamura S, Mingrone E et al (2012) Identification of a subgroup of patients at highest risk for complications after surgical cytoreduction and hyperthermic intraperitoneal chemotherapy. Ann Surg 256:334–341CrossRefPubMed


Hutchins LF, Unger JM, Crowley JJ et al (1999) Underrepresentation of patients 65 years of age or older in cancer-treatment trials. N Engl J Med 341:2061–2067CrossRefPubMed


Polanczyk CA, Marcantonio E, Goldman L et al (2001) Impact of age on perioperative complications and length of stay in patients undergoing noncardiac surgery. Ann Intern Med 134:637–643CrossRefPubMed


Votanopoulos KI, Newman NA, Russell G et al (2013) Outcomes of Cytoreductive Surgery (CRS) with hyperthermic intraperitoneal chemotherapy (HIPEC) in patients older than 70 years; survival benefit at considerable morbidity and mortality. Ann Surg Oncol 20:3497–503CrossRefPubMed


Votanopoulos KI, Swords DS, Swett KR et al (2013) Obesity and peritoneal surface disease: outcomes after cytoreductive surgery with hyperthermic intraperitoneal chemotherapy for appendiceal and colon primary tumors. Ann Surg Oncol 20:3899–904CrossRefPubMedCentralPubMed


Sugarbaker PH, Chang D (1999) Results of treatment of 385 patients with peritoneal surface spread of appendiceal malignancy. Ann Surg Oncol 6:727–731CrossRefPubMed


Bijelic L, Yan TD, Sugarbaker PH (2008) Treatment failure following complete cytoreductive surgery and perioperative intraperitoneal chemotherapy for peritoneal dissemination from colorectal or appendiceal mucinous neoplasms. J Surg Oncol 98:295–299CrossRefPubMed

Only gold members can continue reading. Log In or Register to continue

Mar 14, 2018 | Posted by in ONCOLOGY | Comments Off on Patient Selection for Treatment
Premium Wordpress Themes by UFO Themes